Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent neurologic complications experienced by patients receiving antineoplastic drugs. Involvement of the peripheral nerves may have an important impact on daily activities and lead to severe impairment of the patient’s quality of life (QoL). It seems to be of crucial importance to make a correct and early diagnosis of polyneuropathy and, if possible, spare the patient unnecessary suffering or loss of function. In the preceding article we have presented epidemiology, grading and pathogenesis of the toxic CIPN. The purpose of this article is to review current knowledge of diagnostic techniques, prevention and management strategies in the context of CIPN.
Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity wi...
This review provides an update on the current clinical and preclinical understanding of chemotherapy...
Andreas A Argyriou,1,3 Athanasios P Kyritsis,2 Thomas Makatsoris,3 Haralabos P Kalofonos3 1Departmen...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
Antineoplastic drugs may be neurotoxic and the clinical features frequently include distal sensory l...
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition in patient...
Chemotherapy-induced peripheral neuropathy (CIPN) is a one of the most common and severe cancer trea...
Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is the most prevalent neurological c...
Chemotherapy-induced peripheral neuropathy (CIPN) develops as a challenging nerve-damaging adverse e...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major and potentially dose-limiting adverse e...
Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity wi...
This review provides an update on the current clinical and preclinical understanding of chemotherapy...
Andreas A Argyriou,1,3 Athanasios P Kyritsis,2 Thomas Makatsoris,3 Haralabos P Kalofonos3 1Departmen...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
Antineoplastic drugs may be neurotoxic and the clinical features frequently include distal sensory l...
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition in patient...
Chemotherapy-induced peripheral neuropathy (CIPN) is a one of the most common and severe cancer trea...
Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is the most prevalent neurological c...
Chemotherapy-induced peripheral neuropathy (CIPN) develops as a challenging nerve-damaging adverse e...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major and potentially dose-limiting adverse e...
Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity wi...
This review provides an update on the current clinical and preclinical understanding of chemotherapy...
Andreas A Argyriou,1,3 Athanasios P Kyritsis,2 Thomas Makatsoris,3 Haralabos P Kalofonos3 1Departmen...